🚀 Die Plattform der Zukunft: Loftware Cloud

Erleben Sie unsere zentrale, konvergierte Etikettierungsplattform, die stärker ist als je zuvor und die Anforderungen von Unternehmen jeder Größe erfüllt. Erfahren Sie mehr!

Kontaktieren Sie uns
ProduktĂĽbersicht

February 22, 2024

Blog

Loftware at SCOPE Summit 2024: Three key takeaways

Sarah Hrycyk

Marketing Programs Manager

Our recent attendance at the SCOPE Summit 2024 in Orlando, Florida, gave our team the opportunity to meet with trusted peers and make new connections with some of the brightest minds in the industry who are passionate about advancing clinical trials and clinical research. 

Execution of this vital work requires collaboration, innovation, and strategic decision-making. Now in its 15th year of fostering these joint efforts to advance our medical knowledge inclusive of all stakeholders, the SCOPE Summit 2024 offered attendees the valuable opportunity to stay ahead of current developments within the industry. 

Read on for my three key takeaways from the event.  

#1 The importance of translation technology for labeling 

One of the most complex and lengthiest aspects of life sciences labeling is efficiently managing the wide array of country-specific labels. These are required for multi-national clinical trials, application, and distribution, ensuring that all the label information is correctly translated and that the design and other label elements comply with relevant local regulations.  

To manage these dynamics and stay ahead of the competition, many leading companies are realizing the need for translation technology support for labeling and are now investing in implementing this. Learn how Loftware can significantly reduce the amount of time it takes to create, approve, and print country-specific labels in a recent report. 

#2 Reducing the environmental impact of global clinical trials 

For many life sciences leaders, a key issue is to become more sustainable. Gartner predicts that by 2025, 50% of CIOs will have performance metrics tied to the sustainability of the IT organization and 75% of executives will be responsible for sustainable technology outcomes. 

The industry is acutely aware of its heavy environmental impact, from drug waste to shipping and packaging, and is looking at ways to reduce this. To manage this shift in prioritization, businesses must embrace technologies that not only make their operations more resilient and adaptive but also enable them to meet their sustainability goals. By leveraging the power of the Cloud, companies can improve both visibility and sustainable practices across the supply chain. Discover how your company can create a roadmap for sustainability in the Cloud here. 

#3 Embracing decentralization in clinical trials 

Recent events have led to significantly increased interest in Decentralized Clinical Trials (DCTs), with sponsors eager to embrace models that reduce or eliminate the need for participants to travel to a specific study site for treatment or monitoring. However, despite increased enthusiasm for this method of working, there is no universal definition of a DCT, rather this remains a catchall term for trials that incorporate mechanisms to reduce reliance on a single trial site. 

Our recent report looks at how the industry is rapidly embracing DCTs, what brought about this change and the current challenges faced, the types and definitions of DCTs, as well as what the benefits are of adopting a modern integrated approach through cloud-based platforms. 

  • Cloud
  • Regulatory
  • Clinical Trials